3/20/2024

Meperidine Hydrochloride Injection

Products Affected - Description

- Demerol injection, Pfizer, 100 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-1180-69
- Demerol injection, Pfizer, 50 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-1178-30
- Demerol injection, Pfizer, 50 mg/mL, 1 mL Nexject prefilled syringe 10 count, NDC 00409-1418-01

Reason for the Shortage

- Hikma has meperidine injection available.
- Pfizer has Demerol on shortage due to manufacturing delays.

Available Products

- Demerol injection, Pfizer, 25 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-1176-30
- Demerol injection, Pfizer, 25 mg/mL, 1 mL Nexject prefilled syringe 10 count, NDC 00409-1362-01
- Demerol injection, Pfizer, 50 mg/mL, 30 mL multiple dose vial, 1 count, NDC 00409-1181-30
- Demerol injection, Pfizer, 75 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-1179-30
- Meperidine injection, Hikma, 100 mg/mL, 1 mL vial, 25 count, NDC 00641-6054-25
- Meperidine injection, Hikma, 25 mg/mL, 1 mL vial, 25 count, NDC 00641-6052-25
- Meperidine injection, Hikma, 50 mg/mL, 1 mL vial, 25 count, NDC 00641-6053-25

Estimated Resupply Dates

- Pfizer has Demerol 50 mg/mL 1 mL Carpuject syringes and 100 mg/mL 1 mL Carpuject syringes available in limited supply. The 50 mg/mL 1 mL NexJect syringes are on back order and the company estimates a release date of November 2024.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.